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The contribution of dendritic cell (DC) antigen cross-presentation to the activation of
CD8+ T lymphocytes for immune defense against tumors, viruses, and intracellular
pathogens has been recognized widely. Although originally thought to be an exclusive
characteristic of DCs, recently also other immune cells, particularly macrophages,
have been shown capable of cross-presentation. Here we provide an overview of in
vitro and in vivo evidence on cross-presentation by macrophages. As we discuss,
it is now firmly established that various types of tissue-resident macrophages are
able to cross-present via similar cellular pathways as DCs. This is based on a wide
range of antigens in macrophages from many different tissue origins such as blood,
tumors, and lymphoid tissue. However, the physiological relevance of macrophage
cross-presentation with potential contributions to activation of CD8+ T lymphocytes
is still mostly unknown. While cross-presentation by various types of proinflammatory
macrophages might be involved in cross-priming of naive CD8+ T lymphocytes, it might
also be involved in local reactivation of memory and/or effector CD8+ T lymphocytes.
Moreover, cross-presentation by anti-inflammatory macrophages could be related to
immune tolerance. Because cross-presentation promotes the initiation and potentiation
of antigen-specific CD8+ T lymphocyte responses, stimulating macrophages to cross-
present antigen might be a promising strategy for antitumor or antiviral therapies.
Keywords: tumor immune responses, antigen cross-presentation, vacuolar pathway, macrophages, cytosolic
pathway, T-cell activation, intracellular pathogens
INTRODUCTION
Since the first evidence of their antigen cross-presenting capacities for activation of naive CD8+
T lymphocytes in 1976, dendritic cells (DCs) have been heavily studied for the mechanisms
and physiological roles of cross-presentation (1). Antigen cross-presentation is crucial for the
initiation of adaptive immune responses against cancer, viruses, and numerous other intracellular
pathogens. During this process, antigen-presenting cells (APCs) present peptides derived from
ingested antigens in their major histocompatibility complex class I (MHC-I) protein complex to
naive CD8+ T lymphocytes. If the DCs also provide sufficient levels of costimulatory receptors (e.g.,
CD80, CD86) and cytokines [interleukin 12 (IL-12)], cross-presentation results in the activation of
naive CD8+ T lymphocytes to effector cytolytic T cells in a process called cross-priming. Effector
cytolytic T cells can induce apoptosis in infected or malignant cells (2, 3). Because DCs were
assumed the only (or at least main) cross-presenting cells capable of cross-priming naive CD8+
T lymphocytes, by far most research has been focused on cross-presentation pathways in DCs.
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However, recently also macrophages have been shown to be
capable of antigen cross-presentation, and this might have large
implications for our understanding of CD8+ T lymphocyte
responses. Therefore, the aim of this review is to provide
an overview of the current studies covering the roles and
mechanisms of antigen cross-presentation by macrophages.
Role of Dendritic Cells and Macrophages
in CD8+ T Lymphocyte Activation
During their lifetime, DCs can exist in two discrete stages:
immature and mature. Immature DCs are overall considered
to be better in endocytosis and protein processing, and their
primary role is to sample antigen in the circulation and
peripheral tissues. The recognition of antigen by pattern
recognition receptors (PRRs), such as Toll-like receptors
(TLRs), results in the maturation of the DCs. The resulting
mature DC can migrate to the lymphoid organs, where it
can activate antigen-specific CD8+ T lymphocytes by cross-
presentation (4). Dendritic cells can be categorized into
subsets based on their cross-priming ability and origin. Many
studies are devoted to characterize the capacity of various DC
subsets to cross-present to CD8+ T lymphocytes in mouse
and human by, for example, the use of RNA sequencing and
lineage tracing, which has been extensively reviewed elsewhere
(2, 5, 6). Briefly, the main subsets in human are plasmacytoid
CD123+CD303+CD304+ DCs (pDC) and conventional DCs
(cDCs) including CD1a+CD11chighXCR1−BDCA-1+ (cDC2)
and CD1a−CD11clow CLEC9A+XCR1+BDCA-3+CD141+
(cDC1) (2, 5, 6). All these subsets have the capacity to cross-
present, but because of the high expression of MHC-I pathway
genes, cDC1s are considered as the most efficient cross-
presenting cells in human (2, 5, 6). The same subsets are present
in mice, but then based on expression of CD11c and MHC class
II in combination with CD4, CD8α, CD11b, XCR1, CLEC9a,
CD103, and CD205. The mouse classical DCs express either
CD11b (equivalent to human cDC2) or CD8α, XCR1, CLEC9A
(also known as DNGR1), and CD103 (equivalent to human
cDC1), where the cross-presenting efficiency depends on the
expression of CD8 (in lymphoid tissue), making the classical
CD8+ DC the best mouse subset for activation of cytolytic T
lymphocytes (2, 5, 6).
Tissue macrophages such as liver Kupffer cells, spleen
red pulp, and large peritoneal macrophages develop during
embryogenesis, where they originate from precursors in the yolk
sac, fetal liver, and bone marrow (BM) [extensively reviewed in
Perdiguero and Geissmann (7)]. These embryonically derived
macrophages become tissue-resident macrophages that can
propagate via self-renewal (7, 8). Later in life, the hematopoietic
stem cells in the BM give rise to LY6C+ monocytes in mice or
CD14+CD16+ monocytes in human, which can subsequently be
recruited from the blood into the tissues, such as sites of infection
or tumors, to promote either further inflammation or tissue
repair (8–10). Upon arrival, these monocytes can differentiate
into proinflammatory or anti-inflammatory monocyte-derived
macrophages, depending on the PRR signaling, growth factors,
and cytokines present in the tissue. The proinflammatory,
also known as M1 or classically activated, macrophages are
activated by signaling from PRRs or inflammatory cytokines [e.g.,
interferon γ (IFN-γ)] and express proinflammatory cytokines,
IL-6, tumor necrosis factor α (TNF-α), IL-1β, and inducible
nitric oxide synthase (6, 11). The anti-inflammatory, also
called M2, proresolving or alternatively activated, macrophages
are stimulated by IL-4 or IL-13 and express arginase 1, the
mannose receptor CD206 and the IL-4 receptor α-chain (IL-
4Rα). The main function of the proinflammatory macrophages
is to eliminate tumors and pathogens by production of
inflammatory cytokines and phagocytosis, whereas the main
functions of the anti-inflammatory macrophages are tissue repair
and homeostasis (12–14). When there is space in the tissue niche,
blood-recruited monocytes might also differentiate into tissue
macrophages (8). Both embryonically derived and monocyte-
derived macrophages are able to sense and phagocytose tumor
cells and pathogens (15). The precise phenotype and access to
antigen of tissue-resident macrophages depend on the tissue, but
especially spleen, lymph node, liver, and peritoneal macrophages
(Figure 1) constantly encounter blood- or lymph-borne antigens,
which means that they are ideally positioned for antigen
uptake, and they are thus in principle well-positioned for cross-
presentation to CD8+ T lymphocytes.
Although antigen cross-presentation by macrophages is
less well understood than for DCs, it is increasingly clear
that especially proinflammatory macrophages are capable of
cross-presentation. The function of this cross-presentation is
unclear, but evidence suggests it might be important for cross-
priming of naive CD8+ T lymphocytes similar as in DCs. In
addition, it might aid in the activation of memory CD8+ T
lymphocytes, which are important in case of recurrent infections.
Memory CD8+ T lymphocytes are present in tissues such as
in the skin (16), where they might encounter macrophages.
Additionally, inflammatory macrophages may cross-present
to reactivate effector CD8+ T lymphocytes upon sustained
infections in combination with production of IL-12 and IL-23,
but independent of CD80, CD86, and CD28 costimulation (2). In
contrast, cross-presentation by anti-inflammatory macrophages
might have functions in immune tolerance against “self ”
proteins, commensal microbes, and food components, similar
to the cross-presentation of immature DCs (17). The different
roles of cross-presentation by macrophages possibly relate to
the antigen source, type of macrophage, and location of the





In the spleen, different subsets of macrophages can be
distinguished based on their anatomical location and
function (Figure 1). In mice, the red pulp macrophages
(F4/80highCD68+VCAM1+CD11blow) are involved in iron
metabolism and clearance of senescent erythrocytes. The
white pulp macrophages (F4/80lowCD68+) are specialized in
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FIGURE 1 | Macrophage types potentially capable of antigen cross-presentation. Populations of macrophages in various tissues of the body that can cross-present
antigen and their potential interactions with CD8+ T lymphocytes. Lymph node: blood vessel (red), cortex and follicle (green) with CD8+ T lymphocytes (gray) in the
T-cell zone and subcapsular macrophages on the edge (blue), medulla (brown) including medullary sinus macrophages, medullary cord macrophages and
subcapsular macrophages (blue). Liver: blood vessel (red) containing CD8+ T lymphocytes (gray) and Kupffer cells (blue) on the edge, which are surrounded by
hepatocytes. Tumor environment: tumor-infiltrating macrophages (blue) and CD8+ T lymphocytes (gray) in between tumor cells (brown). Bone marrow: hematopoietic
stem cells (HSCs), which give rise to monocytes (dark blue) that leave the bone marrow by blood vessels (red). Blood: monocytes in the blood vessels (red) can
extravagate through the vessel wall into tissues, where monocytes (dark blue) differentiate into macrophages (blue), and there could be memory T cells (gray) to
reactivate upon infection. Spleen: the spleen consists of red pulp (pink), white pulp (soft pink) with follicles (white) containing CD8+ T lymphocytes (gray), and blood
vessels (red). The red and white pulps are separated by the marginal zone. All contains macrophages (blue), including the marginal zone, which contains marginal
metallophilic and marginal zone macrophages. Peritoneum: the adipocytes (soft yellow) surround the peritoneal cavity (yellow), which includes large and small
peritoneal macrophages (blue) and CD8+ T lymphocytes (gray).
phagocytosis, for instance, for clearance of apoptotic B cells,
and for regulating immune responses against pathogens. The
white and red pulps are separated by the marginal zone, and
macrophages located in this area can recognize and clear
blood-borne antigens. Marginal zone macrophages can be
subdivided in the phenotypically and functionally different
marginal metallophilic macrophages (F4/80lowCD68+CD169+),
involved in virus clearance, and marginal zone macrophages
(F4/80lowCD68+SIGN-R1+), involved in tolerance against
apoptotic cells in blood (18). Given that both types of marginal
zone macrophage encounter blood-borne antigens and the role
of CD169+ macrophages in CD8+ T lymphocyte activation in
the lymph nodes (see below), a role for these macrophages in
CD8+ T lymphocyte activation in the spleen is likely (19, 20).
Evidence that splenic macrophages are capable of cross-
presentation comes from the in vitro finding that isolated
mouse splenocytes incubated with microspheres encapsulated
with the model antigen ovalbumin could induce activation
of ovalbumin-specific B3Z hybridoma cells (LacZ assay)
(21). Macrophages might play a role in this CD8+ T
lymphocyte activation, and it was not exclusively due to
splenic DCs, because ovalbumin-specific T-cell activation (in
vivo cytotoxicity assays) was still observed with splenocytes
from mice that were depleted of CD11c+DCs (21). Moreover,
splenocytes from mice depleted of both CD11c+DCs and
CD11b+macrophages showed less T-cell activation compared to
mice depleted of CD11c+DCs only, suggesting that macrophages
can cross-present in the absence of DCs (21). However, the
ovalbumin-containing microspheres used in this study were
specifically designed for vaccination and thereby might enhance
cross-presentation also in cell types that normally are not
(or less) able of this process. Moreover, the physiological
relevance of this finding is unclear, because CD11c and CD11b
expression alone seems not sufficient to distinguish splenic
macrophages and DCs (5). For instance, although depletion
with CD11c will remove both CD11chiCD11b+CD8α−MHCII+
and CD11chiCD11b−CD8α+MHCII+ cDC subsets (22), the
selection of CD11b is not sufficient to distinguish the various
spleen macrophage populations because this would require
selection onCD169 or SIGN-R1+ (5, 22).Moreover, this isolation
method might result in contamination of the CD11c+ DC
population with CD11cintF4/80high red pulp macrophages (23).
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Recently, these CD11cintF4/80high red pulp macrophages
became of interest because, similar to DCs, they express
CD11c, and their location in the spleen allows them to
acquire blood-borne antigens (23). Indeed, in vitro cross-
presentation of fluorescently labeled ovalbumin by murine
CD11cintF4/80high CD4−CD8−CD11b−CD80+CD86+MHCII+
Gr1−MARCO− red pulp macrophages resulted in faster OT-I
cell proliferation and higher expression of the T-cell activation
markers granzyme-B, TNF-α, and production of IFN-γ than with
the CD11chighCD8α+DEC205+ cDC1 subset (23). These OT-
1 cells activated by the red pulp macrophages did not express
activation markers CD127, KLRG1, and CX3CR1, suggesting
they were so-called early effector cells, which do not develop
into memory cytolytic T cells (23, 24). In contrast to the cDC1
cells, uptake of the model antigen ovalbumin by the red pulp
macrophages relied on the mannose receptor CD206 (23). To
address the role of cross-presentation by red pulpmacrophages in
vivo, mice negative for the transcription factor SpiC were studied
(23). SpiC mice lack CD11cintF4/80high red pulp macrophages,
as SpiC is required for their development, whereas cDC1 DCs
are unaltered because they rely on the transcription factor Batf3
(23, 25). Infection of SpiC knockout OT-1 mice with AdLGO
adenovirus-expressing ovalbumin resulted in a higher initial viral
load, whereas viral clearance by ovalbumin-recognizing OT-I
cytolytic T cells was achieved after 10 days. In contrast, cDC1-
deficient Batf3 knockout mice showed no changes in the initial
viral load, but viral clearance was delayed until day 14 (23).
In line with the KLRG1−CX3CR1− phenotype of the cytolytic
T cells induced by red pulp macrophages in vitro, in vivo
reinfection experiments in SpiC knockout mice showed that red
pulp macrophages are not essential for induction of memory
cytolytic T-cell responses (23). Together, these findings suggest
that cross-priming by red pulp macrophages is necessary to
contain early viral spread by triggering a fast but short antiviral
response, whereas the main function of cDC1 cells is cross-
priming of cytolytic T cells for complete viral clearance and
development of memory cytolytic T cells.
The cross-presentation capabilities of other splenic
macrophages have also been investigated in vivo. First, in
mice with melanoma that underwent thermal ablation,
isolated CD11b+CD11c−CD45+ splenic macrophages were
shown capable of cross-presentation as directly shown with
a fluorescently labeled antibody recognizing MHC-I (H-
2Kb-) loaded with the ovalbumin-derived epitope SIINFEKL
(26). In addition, the CD8+ lymphocytes in the tumor
were specific for the antigen as shown by MHC-I tetramers
carrying this epitope (26). Second, increased numbers of
CD169+F4/80+CD11b+CD45+ macrophages were observed
in the treated tumor region and spleen, which might suggest
a role for these CD169+ macrophages in CD8+ T lymphocyte
activation for elimination of the tumor (26). In line with a
role for macrophages in cross-presentation, depletion of all
phagocytosing cells using clodronate liposomes showed that
after 7 days, when the DCs already repopulate, whereas the
spleen macrophages need 2 weeks, the CD11c+ DCs were unable
to activate OT-I cells (IFN-γ, ovalbumin-specific cytotoxicity)
with ovalbumin targeted by an antibody to the Siglec-1 receptor
(CD169) in vitro (27). In contrast, direct targeting to CD8+ DCs
via ovalbumin conjugated to an antibody recognizing CD205
resulted in efficient activation of CD8+ T lymphocytes in vitro
(27), indicating that directly targeted antigen was cross-presented
by the DCs.
However, a role for DCs in activation of cytolytic T cells
by macrophages cannot be excluded, as the antigen might
be transferred from the macrophages to the DCs (26). Thus,
although, for instance ovalbumin targeted to the receptor
Siglec-1 is ingested by marginal metallophilic macrophages, it
might be subsequently transferred to CD8+ DCs for cross-
presentation to CD8+ T lymphocytes (27). CD8+ DCs not
only reside in the white pulp, but also locate the red pulp
and marginal zone (28), and in principle they could encounter
marginal metallophillic macrophages residing in the latter area.
Migration of the DCs to the marginal zone might be important
for antigen transfer, because treatment of mice with pertussis
toxin, which blocks chemokine receptor–mediated migration,
no longer resulted in OT-I CD8+ T lymphocyte proliferation
using ovalbumin targeted to Siglec-1 (27). In contrast, CD8+
T lymphocyte responses after direct targeting of ovalbumin
to CD8+ DCs via CD205 were unaffected by treatment with
pertussis toxin (27). The CD169+ macrophages and CD8+ DCs
have also been visualized in close interaction with each other
using immunofluorescence microscopy and flow cytometry. In
this case, the CD169+ macrophages were suggested to move to
the CD8+DCs, although this was not specifically shown (29).
Moreover, the specific antigen transfer seems to depend on the
sialoadhesin CD169, which is involved in cell adhesion, because
the use of Sn-KI mice, which expresses a mutated form of CD169,
resulted in a reduced amount of antigen-positive CD8+ DCs
(fluorescent ovalbumin) and a reduced amount of ovalbumin-
specific IFN-γ-producing CD8+ lymphocytes (29). The immune
stimulus of CD169+ macrophages is also important, because in
vivo administration of liposomes targeted to CD169L, present on
CD169+ macrophages, and containing ovalbumin and a TLR7
agonist induced expression of the activation markers CD86 and
CD80 in the CD169+ macrophages and induced in vivo OT-
I CD8+ T lymphocyte activation measured by proliferation,
whereas only OT-II CD4+ T-cell responses were observed in
absence of the TLR7 agonist (30). Altogether, it seems that
murine CD169+ macrophages in the spleen contribute to cross-
presentation either directly or by transferring antigens to CD8+
DCs in the spleen.
Cross-Presentation by Lymph Node
Macrophages
According to their anatomical location in the lymph nodes
and expression of surface markers, lymph node macrophages
can be divided into subcapsular sinus macrophages (SSMs;
F4/80−CD169+), medullary sinus macrophages (MSMs;
F4/80+CD169+), and medullary cord macrophages (MCMs;
F4/80+CD169−) (31) (Figure 1). Many lymph node
macrophages are directly exposed to lymph fluid (31), which
in principle enables them to efficiently take up lymph-borne
antigens to present to T cells (31).
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In vivo evidence that F4/80+CD169+ MSMs and
F4/80+CD169− MCMs are capable of cross-presentation
comes from the finding that only these cells can induce
antitumor effects through stimulation of tumor-specific CD8+
T lymphocytes when targeted by a nanogel packed with tumor-
specific synthetic long peptide antigen (LPA) and a TLR9
agonist (32). In this study, isolated F4/80+CD169+ MSMs,
18 h after injection of the nanogel, were most efficient at
inducing LPA-recognizing DUC18 CD8+ T-cell responses in
vitro measured by IFN-γ production and proliferation, which is
possibly caused by a higher expression of CD80 and CD86 when
compared to MCMs (32). Moreover, DCs and F4/80−CD169+
SSMs did not induce T-cell responses, and thereby, it was
concluded that they were not essential for cytolytic T-cell
activation, probably because they did not have access to the
nanogel. Injection of clodronate-containing liposomes, which
deplete macrophages but less DCs because they regenerate
faster, blocked these antigen-specific CD8+ T lymphocyte
response in the lymph node (32). However, the physiological
relevance of this finding is unclear, given that a highly artificial
antigen was used, and it was not confirmed whether in vivo
the macrophages actually processed the peptide for cross-
presentation, presented it directly on MHC-I, or transferred
it to DCs as described for splenic CD169+ macrophages
(27, 29).
Other in vivo evidence that cross-presentation by CD169+
macrophages might be important in vivo is the finding that mice
specifically depleted of CD169+ SSM and MSM macrophages
by induced expression of diphtheria toxin receptor (DTR)
showed no OT-I CD8+ T lymphocyte responses upon injection
with ovalbumin expressing apoptotic cells or tumors (33).
Additionally, CD169+CD11c+ macrophages were better cross-
presenters compared to CD169+CD11c− macrophages and
CD169−CD11c+CD8+ DCs, as shown by footpath stimulation
with ovalbumin-expressing dead cells, followed by flow sorting
of the DC and macrophage subsets and in vitro culturing
with OT-I cells (proliferation, IFN-γ). Moreover, injection of
CD8α+ DCs in CD169−-depleted mice did not increase OT-
I CD8+ T lymphocyte responses (proliferation, IFN-γ) (33).
Although this result at first glance seems strange given the
essential role of CD8α+ cDCs in CD8+ T lymphocyte activation
(2), DCs are mostly located in the T-cell zone upon arrival
in the lymph node, where the antigens might possibly not
be well accessible to the DCs, whereas the sinus location of
the macrophages is beneficial for the antigen sampling (12).
Additionally, microscopy revealed that CD169+ macrophages
and ovalbumin-specific OT-I CD8+ T lymphocytes are in close
contact already at 4 h after antigen challenging, suggesting that
the CD8+ T lymphocytes relocalize to the sinus to be activated by
antigen cross-presentation and then return to the T-cell zone for
proliferation (33, 34). Thus, CD169+ sinus macrophages might
well activate CD8+ T lymphocytes in the sinus, which would
suggest that they are capable of cross-presentation. This might
explain the physiological relevance of these macrophages and
their location in the sinus and not in the T-cell zone (Figure 1).
Another option is that the CD169+ SSM and MSM might
transfer the antigen to DCs by CD169 to contribute to CD8+
T lymphocyte activation, similar to CD169+ macrophages in the
spleen (see above) (27, 29).
A role for CD169+ macrophages in cross-priming is in line
with in vivo mouse experiments with subcutaneous injection of
antibodies targeting different receptors and complexed with the
model antigen ovalbumin fused to immunoglobulin G–binding
domains of protein G (35). In this study, it was found that
targeting to CD11c, CD40, and TLR2 (all present inDCs) resulted
in the most efficient in vivo cross-priming of OT-I T cells,
whereas targeting to CD207 (expressed strongly by Langerhans
cells) or CD169 (expressed by SSMs) still resulted in stronger
cytolytic T-cell responses than ovalbumin alone (i.e., without
antibody targeting). In addition, microscopy showed that the
protein complexes were ingested not only by CD35+ follicular
DCs, but also by CD169+ cells located in the marginal zone (35).
The cross-presentation capabilities have also been studied
for macrophages from the tonsils. Although CD11c+HLA-
DR+CD14+ macrophages isolated from human tonsils
efficiently ingested fluorescently labeled necrotic cells, in
vitro activation (IFN-γ) of the MelanA-recognizing LT12
CD8+ T-cell clone pulsed with a long peptide fragment of
MelanA was much less efficient for macrophages than for
CD11c+HLA-DR+CD14−BDCA1+ cDC2, CD11c+HLA-
DR+CD14−BDCA3+ cDC1, and CD11c−HLA−DR+ pDC
tonsil DCs (36). Also, the in vitro cross-presentation of NS3
protein from hepatitis C to NS3 antigen-specific CD8+ T-cell
clones (IFN-γ) was less efficient for CD11c+HLA-DR+CD14+
tonsil macrophages than for these DC subsets (36). These
findings show that although tonsil macrophages might in
principle be able to cross-present antigens, they are less capable
than the major DC subsets.
Cross-Presentation by Liver Macrophages
The macrophages in the liver are called Kupffer cells. This
very heterogeneous cell population (37) plays a major role in
the clearance of gut-derived antigens and pathogens from the
blood, making them in principle ideally positioned for cross-
presentation to blood CD8+ T lymphocytes. However, studying
the Kupffer cells is challenging because of loss of cells during
isolation and lack of consistent cell-membrane markers for
sorting (37).
Murine hepatic cells cultured in vitro with the model antigen
ovalbumin could induce proliferation of ovalbumin-recognizing
TH1 HTL clone cells but not TH2 HTL cells (38, 39). Although
this cell mixture included Kupffer cells, the contribution of
other hepatic cells, such as liver resident DCs, liver endothelial
cells, and hepatocytes, cannot be excluded. Indeed, a recent
side-by-side comparison of ovalbumin-pulsed hepatocytes, Tie-
2+CD11blow liver endothelial cells, and CD11b+F4/80+ Kupffer
cells showed that all these cell types can induce OT-I CD8+
T lymphocyte proliferation in vitro with similar efficiency as
splenic CD11c+DCs (40). However the physiological role in the
initiation of cytolytic T-cell responses by liver cells is unclear,
because the levels of cytolytic T-cell activation markers (CD44,
CD25) and IFN-γ production were lower in the proliferated OT-
I CD8+ T lymphocytes upon stimulation by the liver cells than
upon stimulation with CD11c+ DCs (40).
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Interestingly, Kupffer cells seem to suppress immune
responses for immune tolerance as seen in murine
transplantation studies by rejection of allogeneic liver transplants
(41). Injection of Carboxyfluorescein succinimidyl ester (CFSE)-
labeled OT-I CD8+ lymphocytes in the portal vein and
intraperitoneal injection of ovalbumin peptide resulted in
retention of activated OT-I CD8+ cells (proliferation and
CD45 expression) in the liver, followed by their deletion,
probably by apoptosis as shown by DNA fragmentation (42).
This apoptosis seems to be dependent on interactions with
the Kupffer cells because CSF-1–deficient mice, which have no
mature developed tissue macrophages because CFS-1 is essential
for their differentiation, resulted in an increased presence of
activated OT-I CD8+ lymphocytes (proliferation and CD45
expression) (42). Thus, it seems that Kupffer cells are capable of
cross-presentation, and although the physiological relevance of
this is still unclear, this might play a role in immune tolerance.
Cross-Presentation by Tumor-Infiltrating
Macrophages
The immune system can either combat cancer by
immunosurveillance where the cancer is recognized and
cross-presented by APCs (43) or promote tumor progression
via (in)direct suppression of CD8+ T lymphocytes and other
immune cells (43, 44). When directly comparing cross-
presenting capacities of DCs and primary macrophages isolated
from human peritoneal tumor ascites in vitro, it was found
that HLA-DR+CD11c+CD1c−CD16+ tumor macrophages
are even more effective than HLA-DR+CD11c+CD1c+CD16−
DCs at cross-presentation to the LT12 CD8+ T-cell lines
(IFN-γ) recognizing the tumor-specific antigen MelanA, which
does not require costimulation for activation (45). Moreover,
thermal ablation of ovalbumin-expressing melanoma in mice
resulted in increased cross-presentation of ovalbumin-derived
epitopes by intratumoral CD11b+CD11c− macrophages as
directly measured by an antibody that recognizes MHC-I loaded
with SINFEKL (26). Additionally, this cross-presentation was
concomitant with an increased presence of ovalbumin-specific
CD8+ T lymphocytes (26). Although these findings support
a role for macrophages in ovalbumin-specific CD8+ T-cell
responses, evidence shows that DCs are essential in the initial
activation of the naive CD8+ T lymphocytes.
Although human ascites monocyte-derived CD1a+CD16+
macrophages efficiently presented a MelanA epitope to the LT12
CD8+ T-cell clone in vitro, cross-priming of allogeneic naive
cytotoxic CD8+ T cells (proliferation and expression of granzyme
A, perforin, IFN-γ) was only observed by ascites monocyte-
derived DCs and not ascites monocyte–derived macrophages
(45). The reason for this is that the ascites monocyte-derived
macrophages lacked expression of costimulatory signals such as
CD80 and CD86 and produced almost no IL-12, whereas these
were expressed by the ascites monocyte-derived DCs (45). These
findings indicate that although tumor-infiltrating macrophages
are capable of cross-presentation, they do not provide the
costimulatory signals required for cross-priming of cytolytic
T cells.
More indirect evidence on cross-presentation by tumor-
infiltrating macrophages was obtained in a microscopy study
in mice showing that migrating OT-I CD8+ T lymphocytes
in ovalbumin-expressing tumors can have long interactions
with F4/80+ macrophages, which might suggest activation by
cross-presentation (46). Furthermore, CD8+ T lymphocytes
might be activated for virus peptide by macrophages, because
tumors in mice caused by injected fibrosarcoma cells transfected
with lymphocytic choriomeningitis virus [MCA102(gp33)] were
infiltrated by CD8+ T lymphocytes, a few CD11c+ DCs and
a high number of CD11b+ macrophages (44). However, these
tumor-infiltrating CD8+ T lymphocytes exhibited a highly
activated phenotype (upregulated CD25, CD44, and CD69 and
down-regulated CD62L expression) but lacked effector cell
function, measured by a killing assay, suggesting modulation
of the CD8+ T lymphocytes by the tumor environment.
The tumor-infiltrating CD11b+ macrophages were also able
to efficiently cross-present to tumor infiltrating CD8+ T
lymphocytes (proliferation, IFN-γ, cytolytic activity) for gp33 in
vitro (44). However, the costimulatory molecules CD80, CD86,
and ICAM-1 were not expressed in these macrophages, which





In DCs, antigen cross-presentation can be the result of two
distinct cellular pathways: the cytosolic and vacuolar pathway
(2, 47). In the cytosolic pathway, proteins are first transported
from the lumen of the endosomal compartment to the cytosol
for degradation by the proteasome. Subsequently, the derived
peptides can be processed via the MHC-I presentation pathway.
The peptides are relocated via the transporter associated with
antigen presentation (TAP) into the endoplasmic reticulum
(ER), where they are processed by ER aminopeptidases, or
brought back into the antigen-containing endosomes to be
processed by insulin-regulated aminopeptidase. The loading of
peptides on MHC-I occurs within these compartments (2, 17).
The other main cross-presentation pathway is the vacuolar
pathway, where proteins are processed by endosomal/lysosomal
proteases, such as cathepsin S, and loaded on MHC-I within the
endosomal/lysosomal compartments (2, 17). As we will discuss
below, evidence suggests that the vacuolar pathway seems to be
predominantly used by macrophages, although they might be
able to also cross-present via the cytosolic pathway.
Bone Marrow and Blood
Monocyte-Derived Macrophages
Cross-Present via the Vacuolar Pathway
Monocytes derived from hematological precursors in the BM
can migrate via the blood stream to other tissues, where they
can differentiate into macrophages to perform tissue specific
functions, eliminate pathogens, or restore tissue homeostasis
(48). Therefore, for research on mouse macrophages, stem cells
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are frequently isolated from the BM and differentiated into
macrophages in vitro. For research on human macrophages,
CD14+monocytes are often isolated from the blood. Both are
then differentiated into macrophages in vitro, either by the
use of macrophage colony-stimulating factor (M-CSF), which
results in a homogenous macrophage population, or by the
use of granulocyte–macrophage (GM)-CSF, which results in a
cell population reflecting resident macrophages (6). However,
GM-CSF is also used to differentiate DCs from monocytes;
therefore, the macrophage culture might contain DCs (5, 6).
Thereby, it should be kept in mind that in vitro–cultured
monocyte-derived macrophages and monocyte-derived DCs
have similarities (5, 6) and that both in vitro BM-derived
and monocyte-derived macrophages and DCs are artificial cell
populations that might not be identical to their in vivo murine
and human counterparts (Figure 1).
The cross-presenting capacities of BM macrophages seem
to be higher than BM DCs when tested side-by-side using
liposomes encapsulating a mixture of the model antigen
ovalbumin and the pore-forming protein sticholysin II.
Macrophage colony-stimulating factor–differentiated BM
macrophages were better in activating the ovalbumin-
recognizing B3Z CD8+ T-cell line (which does not require
costimulation) than GM-CSF–differentiated BM-derived
DCs in vitro (49). This could be explained by the lower
ability of the DCs to internalize the antigen-containing
liposomes (49). Furthermore, inhibitors of the lysosomal
proteases cathepsins and leupeptin resulted in a reduced
efficiency of B3Z T-cell activation by the BM macrophages,
whereas a proteasome inhibitor (epoxomicin) had no effect
(49). This suggests that ovalbumin is processed for cross-
presentation in lysosomes instead of the cytosol and therefore
that cross-presentation occurs via the vacuolar pathway in
BM-derived macrophages.
In line with the conclusion that BM-derived macrophages
cross-present via the vacuolar pathway, the proteasome inhibitor
lactacystin did not inhibit cross-presentation of fluorescein
isothiocyanate–labeled ovalbumin peptide complexed with heat
shock protein to CD8OVA1.3 T hybridoma cells (colorimetric
bioassay for IL-2) in M-CSF–differentiated BM macrophages,
activated 48 h with IFN-γ, whereas there was only a slight
reduction in activation when TAP-deficient macrophages were
used (50). In contrast to BMmacrophages, proteasome inhibition
resulted in a marked reduction of CD8OVA1.3 T hybridoma cell
activation by GM-CSF–differentiated BM DCs (50), suggesting
that these macrophages and DCs use different pathways for
cross-presentation. Final evidence that BM macrophages employ
the vacuolar pathway for cross-presentation comes from the
finding that cross-presentation of ovalbumin to B3Z T cells by
MAC-1+ BM macrophages was reduced by a peptide aldehyde
inhibitor that also inhibits lysosomal proteases (LLnL), whereas
a proteasome inhibitor (LLM) had no effect and resulted in
normal B3Z T-cell activation (51). Thus, whereas BM DCs can
use the cytosolic route of cross-presentation, antigens seem to
be predominantly cross-presented by BM macrophages via the
vacuolar pathway. This would explain why BM macrophages
have lower expression and activity of the NADPH oxidase
NOX2, which is essential for cross-presentation via the cytosolic
pathway (52, 53).
Fewer data are available on cross-presentation mechanisms
in human monocyte-derived macrophages. They can also
cross-present via the vacuolar pathway similar to murine
BM macrophages, because an in vitro study showed that
the proteasome inhibitor lactacystin did not impair cross-
presentation by human blood monocyte-derived CD1a+CD16+
macrophages of MelanA antigen to CD8+T-cell LT12 clones
(IFN-γ), whereas lysosomal cysteine protease inhibition (with
a pan-cathepsin inhibitor) impaired activation of this T-
cell line (45). These results support that monocyte-derived
macrophages can cross-present via the vacuolar pathway,
which might explain why lysosomal proteases are expressed
in higher levels in human monocyte-derived CD1a+CD16+
macrophages compared to monocyte-derived CD1a+CD14+
DCs (45). However, for various HIV-1 epitopes, evidence
suggests that monocyte-derived macrophages can cross-present
via both the cytosolic and vacuolar pathways. Proteasome
inhibition by MG132 or epoxomicin did not completely block
activation (IFN-γ) of epitope-specific CD8+ T lymphocyte
clones by lipopolysaccharide (LPS) and R848maturedmonocyte-
derived macrophages, suggesting both proteasome-dependent
and -independent processing, although inhibition of lysosomal
cysteine proteases by E64 did not affect cross-presentation
(54). In line with this notion that human monocyte-derived
macrophages might cross-present via both the cytosolic and
vacuolar pathways, similar to DCs, is that the difference in
expression levels of NOX2, required for the cytosolic route of
cross-presentation, is less clear for human monocyte-derived
macrophages and DCs (55) than for murine BM macrophages
and BM DCs (52).
Besides the macrophage types described so far, a new
murine F4/80+ subset of APCs was described containing
characteristics of both macrophages (CD64+MERTK+) and
cDC2s (CD11chiMHCIIhiCD11b+CD24+CD64+CD169+),
while being from mouse monocyte origin (56). These hybrid
DC macrophages have been found in multiple tissues including
lymph node and spleen, and they seem increased in the tumor
microenvironment. Supporting a functional role in the tumor
environment, these cells are efficient at B16 tumor cell uptake
(GFP-labeled), and in vivo blocking of CSF1R-positive cells
(blocking most macrophages, including the new DCmacrophage
hybrid subset) significantly decreased antigen cross-presentation
to ovalbumin-specific OT-I CD8+ T lymphocytes (proliferation)
(56). Moreover, when isolating these DC macrophage hybrid
cells from lymph nodes of mice inoculated with ovalbumin-
expressing cancer cells and in vitro culturing them with
OT-I CD8+ T lymphocytes, efficient T-cell proliferation was
observed (56).
Splenic Red Pulp Macrophages
Cross-Present via the Cytosolic Pathway
As discussed above, both in vitro and in vivo evidence indicates
that murine CD11cintF4/80high red pulp macrophages from
spleen are capable of cross-presentation (23). At least for the
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model antigen ovalbumin, evidence shows that they process this
antigen via the cytosolic pathway. Following its uptake via the
mannose receptor CD206, microscopy showed that fluorescently
labeled ovalbumin colocalizes with the mannose receptor to early
endosomes but not to late endosomes in CD11cintF4/80high red
pulpmacrophages (23). In vitro cross-presentation toOT-I T cells
was almost completely blocked by the TAP-inhibitor UL49 and
the proteasome inhibitor epoxomicin (23), indicating that red
pulp macrophages cross-present via the cytosolic pathway.
Peritoneal Macrophages Cross-Present via
Both Cellular Pathways
There are two subsets of peritoneal macrophages: large peritoneal
macrophages (F4/80high, MHC-IIlow) that play a role in
maintaining homeostatic conditions in the peritoneal cavity
and represent an anti-inflammatory type, and small peritoneal
macrophages (F4/80low, MHCIIhigh), which are important during
inflammation (57) (Figure 1). The large peritoneal macrophages
express higher levels of TLR-4 and costimulatory molecules
(CD80/CD86/CD40). Likely, both peritoneal macrophage types
can cross-present (58–61), but there is contrasting evidence
whether peritoneal macrophages use the vacuolar or cytosolic
pathway. The yield of macrophages from the peritoneum is
low; therefore, mice are often prestimulated with thioglycolate,
which recruits immature macrophages into the peritoneum.
Thioglycolate isolated peritoneal macrophages resemble mostly
small peritoneal macrophages, but have an atypical morphology
and function that is not consistent with the phenotype of tissue
macrophages, but more with monocyte-derived macrophages
(62). Moreover, during the isolation, they can come in contact
with LPS from the used broth, which is ingested by the
macrophages, and as a result, they are able to respond to IFN-
γ priming without any other stimulation (63). A better option
for isolation of peritoneal macrophages for cross-presentation
and phagocytosis studies is called Bio-Gel–elicited macrophage
isolation, which makes use of Bio-Gel beads that cannot be
phagocytosed (63).
The angiotensin-converting enzyme (ACE) 10/10 mice
overexpress the peptidase ACE, which is a peptidase normally
located within the ER and involved in generation of MHC-
I epitopes. Angiotensin-converting enzyme is also involved
in cross-presentation probably following its transfer antigen-
containing phagosomes or endosomes (2, 61). The injection of
ovalbumin-pulsed peritoneal macrophages isolated from ACE
10/10 mice (using thioglycolate) and ovalbumin-specific OT-
1 CD8+ T lymphocytes into a wild-type mouse resulted in
proliferation of the CD8+ T lymphocytes (61). Moreover,
upregulation of the CD8+ T lymphocyte activation marker CD69
occurred faster with peritoneal macrophages isolated from the
ACE 10/10 mice than with macrophages isolated from wild-
type mice (61). Although these studies rely on overexpression
of ACE, these findings indicate that peritoneal macrophages in
principle can cross-present antigen (61). Moreover, as ACE is
potentially transferred from the ER to the lumen of antigen-
containing endosomes (61), these findings suggest that peritoneal
macrophages can cross-present via the vacuolar pathway.
More direct evidence that peritoneal macrophages can
cross-present comes from the finding that a murine peritoneal
macrophages cell line that recombinantly expresses IFN
regulatory factor 7 was able to induce activation of ovalbumin-
specific OT-I CD8+ T lymphocytes in vitro (IL-2 production
and CD40, CD80, and CD86 expression) (58). This activation
could be inhibited by a proteasome inhibitor (lactacystin)
(58), suggesting that the cytosolic pathway was used for cross-
presentation of the antigen. Also the uptake by peritoneal
macrophages of Escherichia coli in which ovalbumin was
expressed could trigger activation (IL-2 production) of the
ovalbumin-recognizing B3Z CD8+ T-cell line (60). These
ingested E. coli bacteria remained in phagosomes that fused
with lysosomes (60), suggesting processing of the bacteria for
cross-presentation via the vacuolar pathway in this case.
Murine peritoneal macrophages also cross-presented virus-
like particles containing the immunodominant epitope (p33)
of lymphocytic choriomeningitis virus in vitro as observed by
increased antigen-specific transgenic CD8+ T-cell proliferation,
but with a reduced efficiency compared to peritoneal isolated
DCs (59). The DCs used both the TAP-dependent and
independent pathway for cross-presentation (59), but there
was no difference in activation of CD8+ T lymphocytes
between TAP1-deficient peritoneal macrophages (thioglycolate
stimulated) and wild-type controls, suggesting the use of the
TAP-independent vacuolar pathway (59). Finally, murine
peritoneal macrophages (thioglycolate stimulated) showed
efficient cross-presentation of ovalbumin encapsulated in
polylactic-co-glycolic acid particles to the B3Z CD8+ T-cell line
in vitro, and these particles resided in LAMP1-positive lysosomes
even 48 h after phagocytosis (64). Based on this observation, it
was suggested that the antigenic proteins might be translocated
from the endosomal/lysosomal compartments to the cytosol.
However, it might also be possible that the antigen is processed
by endosomal/lysosomal proteases, and cross-presentation
occurs via the vacuolar pathway.
To target cross-presentation by peritoneal macrophages, the
effect of downregulation of various signaling pathways has been
investigated. Compared to macrophages isolated from wild-type
mice, CD11b+F4/80+ peritoneal macrophages (thioglycolate
stimulated) from signal transducer and activator of transcription
(STAT) 3 knockout mice were able to stimulate more potent
OT-1 CD8+ T lymphocyte proliferation and IFN-γ production
in vitro with irradiated tumor cells expressing ovalbumin (65).
Similar observations were made with a different antigen derived
from the influenza protein hemagglutinin in combination with
hemagglutinin-recognizing CD8+ T lymphocytes isolated from
CLN4 transgenic mice (65). Because STAT3 is activated by
inflammatory cytokines, such as IL-6, this finding indicates that
cross-presentation by peritoneal macrophages is influenced by
the tissue environment. The increase in ovalbumin-recognizing
CD8+ T lymphocyte activation was not seen for STAT4 or
STAT6 knockout mice (65). Additionally, the antigen VSV8 in a
complex with heat shock protein gp96 was more efficiently cross-
presented (cytotoxicity by 51Cr release) to VSV-specific cytotoxic
T cells in vitro by mice peritoneal macrophages compared
to the antigen alone (66), again indicating that the form of
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the antigen plays an important role for cross-presentation by
peritoneal macrophages.
So, although these results clearly show that peritoneal
macrophages are able of cross-presentation in vitro, the in vivo
relevance remains unclear because of the highly artificial nature
of the antigen and the lacking definition of the used peritoneal
macrophage subset.
CONCLUDING REMARKS
As discussed in this review, many macrophage types seem
capable of antigen cross-presentation with similar, or even better,
efficiency as DCs. Moreover, macrophages seem to employ
mostly the vacuolar pathway of cross-presentation, whereas DCs
use both the vacuolar and cytosolic pathways. Especially the
cross-presenting abilities of macrophages in the spleen, liver and
lymph nodesmight be physiologically relevant, because they have
easy access to blood-borne antigens, whereas for the DCs, this
access might be restricted. However, the role of macrophages in
CD8+ T lymphocyte activation should be further investigated,
because CD169+ macrophages might not activate the CD8+ T
lymphocytes themselves but could transfer antigen to DCs by
CD169 (20). The role of CD169+ macrophages should therefore
be further investigated, and it should be investigated if they
directly cross-present to CD8+ T lymphocytes in vivo or transfer
the antigen to DCs (27, 29).
As apparent from this review, the in vivo roles and
cellular pathways of macrophage cross-presentation are mostly
unknown. One important reason for this is that the isolation of
the specific macrophage types is technically challenging because
(i) surface markers overlap resulting in contamination with other
cell types, and (ii) low numbers of primary macrophages can be
isolated (63). Moreover, the available in vivo research on cross-
presentation bymacrophages is almost exclusively focused on the
effect of vaccination strategies, such as liposomes encapsulating
antigen, where CD8+ T lymphocyte activation markers and/or
proliferation are used as the sole measures of cross-presentation.
Although CD8+ T lymphocyte activation and proliferation
depend on cross-presentation, they also depend on other factors
such as costimulation by cytokines (e.g., IL-12) and costimulatory
receptors (e.g., CD80, CD86) (2). This costimulation is
generally stronger present in DCs than macrophages, and
it is particularly absent in the alternatively activated anti-
inflammatory macrophages. Using T-cell activation as the
sole readout might thereby result in overlooking cross-
presentation capabilities in macrophage types that do not
provide costimulation, whereas this might have important roles,
for instance, in maintenance and/or restoration of immune
tolerance. Cross-presentation by immature/inactivated DCs has
been suggested to allow maintenance of tolerance (67), and it
might well be that cross-presentation by Kupffer cells and/or
anti-inflammatory macrophages plays a similar role (41, 42).
Therefore, the macrophage cross-presenting capabilities and
pathways should be further elucidated, for instance, in vitro by
exposing the cells to antigens and measuring cross-presentation
directly using antibodies (26, 27) followed by measuring
their ability to activate CD8+ T-cell lines that do not need
costimulation. However, because environmental factors might
be needed, these in vitro experiments should be performed in
parallel with in vivo experiments. To determine if a particular
macrophage type is needed for efficient CD8+ T lymphocyte
activation in vivo, this macrophage type could be depleted using
DTR mice as previously explained (68, 69). However, this relies
on surface marker expression and is not effective if the targeted
macrophage type does not express a unique surface marker.
It is increasingly clear that not only DCs and macrophages
can cross-present antigens, but also many other endocytic cell
types are capable of cross-presentation, including monocytes
(70, 71), B cells (72), neutrophils (73), and endothelial cells (74).
The physiological roles of cross-presentation by these diverse
cell types are still unclear, but it seems likely that this also
allows the potentiation of CD8+ T lymphocyte responses or the
maintenance or restoration of immune tolerance.
Lastly, studies on cross-presentation have focused on direct
CD8+ T lymphocyte activation, but the potential role of
tissue macrophages in development and reactivation of memory
CD8+ T lymphocytes has hardly been investigated. Although
CD11cintF4/80high splenic red pulpmacrophages are not essential
for development of memory CD8+ T lymphocytes (23), it
might well be that other macrophage types are involved in
this process or that macrophages are capable of reactivation
of memory CD8+ T lymphocytes upon recurrent immune
challenges (75, 76). Recently, there is a growing interest in
the activation of memory T cells in the tissues and lymphatic
system, which can confer rapid host protection upon cognate
antigen-mediated activation and results in direct killing of
infected cells (75, 76). Especially tissue-resident macrophages
might be important in the development and reactivation
of tissue-resident memory CD8+ T lymphocytes by rapid
and local cytokine secretion during re-infection (74). It is
increasingly clear that macrophages can provide factors such
as chemokines and cytokines that regulate the localization,
differentiation, and survival of tissue-resident memory T
cells (73). Moreover, monocyte-derived APCs provide TNF
superfamily costimulatory signals, which substantially increase
the formation of tissue-resident memory T cells during viral
infection (73).
Because macrophages can cross-present and thereby might
aid in CD8+ T lymphocyte responses, stimulating macrophages
to cross-present might be a promising strategy for antitumor or
antiviral therapies.
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